[{"address1": "171 Oyster Point Blvd", "address2": "Suite 300", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 850 5070", "website": "https://www.mazetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.", "fullTimeEmployees": 125, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.", "age": 49, "title": "CEO & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 812262, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Harold S. Bernstein M.D., Ph.D.", "age": 65, "title": "President of Research & Development and Chief Medical Officer", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 764167, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Courtney J. Phillips J.D.", "age": 50, "title": "General Counsel & Corporate Secretary", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 354780, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Misbah  Tahir CPA", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vipin  Vijayakumar", "title": "Vice President of R&D Infrastructure and Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Krause", "title": "Senior Vice President of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Atul  Dandekar", "age": 53, "title": "Chief Strategy & Business Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Bachrodt", "title": "Senior Vice President of Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nazila  Habibizad", "age": 62, "title": "Senior Vice President of Technical Operations & Supply Chain", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Maarten  Hoek", "title": "Senior Vice President of Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 39.81, "open": 39.84, "dayLow": 39.835, "dayHigh": 41.44, "regularMarketPreviousClose": 39.81, "regularMarketOpen": 39.84, "regularMarketDayLow": 39.835, "regularMarketDayHigh": 41.44, "payoutRatio": 0.0, "forwardPE": -12.893983, "volume": 227122, "regularMarketVolume": 227122, "averageVolume": 401934, "averageVolume10days": 321340, "averageDailyVolume10Day": 321340, "bid": 40.44, "ask": 41.12, "bidSize": 1, "askSize": 1, "marketCap": 1961829760, "fiftyTwoWeekLow": 6.71, "fiftyTwoWeekHigh": 43.29, "allTimeHigh": 43.29, "allTimeLow": 6.71, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 37.8792, "twoHundredDayAverage": 21.6195, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1602077696, "profitMargins": 0.0, "floatShares": 27045534, "sharesOutstanding": 48119444, "sharesShort": 2605655, "sharesShortPriorMonth": 2220820, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.0542, "heldPercentInsiders": 0.018819999, "heldPercentInstitutions": 0.86560994, "shortRatio": 5.57, "shortPercentOfFloat": 0.064899996, "impliedSharesOutstanding": 48119444, "bookValue": 7.892, "priceToBook": 5.165991, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -101458000, "trailingEps": -2.56, "forwardEps": -3.16194, "enterpriseToEbitda": -12.141, "52WeekChange": 1.4959247, "SandP52WeekChange": 0.14725316, "quoteType": "EQUITY", "currentPrice": 40.77, "targetHighPrice": 60.0, "targetLowPrice": 34.0, "targetMeanPrice": 48.33333, "targetMedianPrice": 48.0, "recommendationMean": 1.1, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 383935008, "totalCashPerShare": 7.979, "ebitda": -131957000, "totalDebt": 24183000, "quickRatio": 17.395, "currentRatio": 17.696, "totalRevenue": 0, "debtToEquity": 6.373, "revenuePerShare": 0.0, "returnOnAssets": -0.27371, "returnOnEquity": -0.52686, "grossProfits": 0, "freeCashflow": -68289752, "operatingCashflow": -106662000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MAZE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Maze Therapeutics, Inc.", "marketState": "CLOSED", "exchange": "NGM", "messageBoardId": "finmb_602685968", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.41145, "regularMarketPrice": 40.77, "shortName": "Maze Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1768602585, "regularMarketTime": 1768597201, "postMarketChangePercent": 0.0, "postMarketPrice": 40.77, "postMarketChange": 0.0, "regularMarketChange": 0.959999, "regularMarketDayRange": "39.835 - 41.44", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 401934, "fiftyTwoWeekLowChange": 34.06, "fiftyTwoWeekLowChangePercent": 5.076006, "fiftyTwoWeekRange": "6.71 - 43.29", "fiftyTwoWeekHighChange": -2.5200005, "fiftyTwoWeekHighChangePercent": -0.058212068, "fiftyTwoWeekChangePercent": 149.59247, "earningsTimestampStart": 1762894800, "earningsTimestampEnd": 1762894800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.56, "epsForward": -3.16194, "epsCurrentYear": -3.07221, "priceEpsCurrentYear": -13.270577, "fiftyDayAverageChange": 2.8908005, "fiftyDayAverageChangePercent": 0.076316305, "twoHundredDayAverageChange": 19.150501, "twoHundredDayAverageChangePercent": 0.8857976, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2025-01-31", "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1738333800000, "displayName": "Maze Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-17"}]